This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT05929066 |
|---|---|
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 2,335 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea |
| Interventions | Retatrutide; Placebo |
| Start | Jul 10, 2023 |
| Primary completion | Apr 6, 2026 |
| Study completion | Apr 30, 2026 |
| Results posted | Not yet |
| Registry last updated | Aug 21, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percent Change From Baseline in Body Weight | Baseline, Week 80 |
| Change from Baseline in Apnea-Hypopnea Index (AHI) Events Per Hour for GSA1 Subset | Baseline, Week 80 |
| Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score for GOA1 Subset | Baseline, Week 80 |
| Percent Change from Baseline in Body Weight in Participants in Extension Subset | Baseline, Week 104 |
49 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
